The Centre on Wednesday took steps to accelerate domestic vaccine production. Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech.With the aim of .
The Department of Biotechnology has given permission to HBPCL for producing Covaxin under Mission Covid Suraksha. Covaxin has been developed by Bharat Biotech in collaboration with ICMR.
2021-06-02 11:35:32 GMT2021-06-02 19:35:32(Beijing Time) Xinhua English
MUMBAI, June 2 (Xinhua) India s state-owned Haffkine BioPharma has entered into a technology transfer pact with the country s vaccine producer Bharat Biotech to produce 228 million doses per annum of COVID-19 vaccine, the government s Press Information Bureau said Wednesday.
The Mumbai-based Haffkine BioPharma will produce these vaccines at its Parel complex located in the central part of the city.
Bharat Biotech has developed India s indigenous COVID-19 vaccine in collaboration with two state-owned agencies - Indian Council of Medical Research and National Institute of Virology using whole-virion inactivated vero cell derived platform technology under the brand name Covaxin.